JP2008500375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500375A5 JP2008500375A5 JP2007515532A JP2007515532A JP2008500375A5 JP 2008500375 A5 JP2008500375 A5 JP 2008500375A5 JP 2007515532 A JP2007515532 A JP 2007515532A JP 2007515532 A JP2007515532 A JP 2007515532A JP 2008500375 A5 JP2008500375 A5 JP 2008500375A5
- Authority
- JP
- Japan
- Prior art keywords
- natriuretic compound
- natriuretic
- modifying moiety
- formula
- compound complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002934 diuretic Substances 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 32
- 230000001452 natriuretic Effects 0.000 claims 32
- 101700067009 lys-3 Proteins 0.000 claims 2
- 101700029358 ANF39 Proteins 0.000 claims 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 claims 1
- 102400001289 Atrial natriuretic peptide Human genes 0.000 claims 1
- 101700008793 BNP Proteins 0.000 claims 1
- 230000036912 Bioavailability Effects 0.000 claims 1
- 108010082834 Brain Natriuretic Peptide Proteins 0.000 claims 1
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims 1
- 108010050286 Dendroaspis natriuretic peptide Proteins 0.000 claims 1
- 210000003722 Extracellular Fluid Anatomy 0.000 claims 1
- 102200035782 GOLGA2 R30K Human genes 0.000 claims 1
- 230000036499 Half live Effects 0.000 claims 1
- 102200050814 IFNLR1 K3R Human genes 0.000 claims 1
- 101710040071 NPPC Proteins 0.000 claims 1
- 102100016360 NPR1 Human genes 0.000 claims 1
- 101700008638 NPR1 Proteins 0.000 claims 1
- 102200020420 TSSK2 K27R Human genes 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000001396 anti-anti-diuretic Effects 0.000 claims 1
- 230000000975 bioactive Effects 0.000 claims 1
- 230000035514 bioavailability Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 230000001808 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000004059 degradation Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000001882 diuretic Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002255 enzymatic Effects 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
- 102220008913 rs33960103 Human genes 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 101700017856 vnp Proteins 0.000 claims 1
Claims (19)
- ナトリウム利尿分子NPR−A結合部位と、少なくとも1つの修飾部分複合部位と、を含む生物活性ナトリウム利尿化合物と、
前記修飾部分複合部位に付着した少なくとも1つの修飾部分と、
を含むナトリウム利尿化合物複合体であって、
前記ナトリウム利尿化合物複合体が、対応する非複合ナトリウム利尿化合物に対して酵素分解に対する耐性の増大、循環半減期の増大、バイオアベイラビリティの増大、および効果の持続期間の延長から成る群から選択される1つもしくはそれ以上の利点を示す、ナトリウム利尿化合物複合体。 - 前記ナトリウム利尿化合物が、ペプチド、もしくは脳ナトリウム利尿ペプチドの生物活性ペプチド断片、心房性ナトリウム利尿ペプチド、C型ナトリウム利尿ペプチド、またはデンドロアスピス(dendroaspis)ナトリウム利尿ペプチドを含む、請求項1に記載のナトリウム利尿化合物複合体。
- 前記ナトリウム利尿化合物が、Lys3Arg、Lysl4Arg、Arg30Lys、Lys27Arg、およびArg31Lysから成る群から選択される1つもしくはそれ以上の変異体を有する天然hBNP配列を含む、請求項1に記載のナトリウム利尿化合物複合体。
- 前記ナトリウム利尿化合物が、1つもしくはそれ以上の挿入、欠失、または伸長を有する天然hBNP配列を含む、請求項1に記載のナトリウム利尿化合物複合体。
- 過剰なレベルの細胞外液の治療のための薬剤の製造における、請求項1ないし7のいずれに記載のナトリウム利尿化合物複合体の使用。
- 前記ナトリウム利尿化合物が、hBNPである、請求項5ないし13のいずれかに記載のナトリウム利尿化合物複合体。
- 前記ナトリウム利尿化合物が、hBNPであり、前記修飾部分がLys3で結合されており、かつ前記ナトリウム利尿化合物複合体が、モノ複合体である、請求項5ないし13のいずれかに記載のナトリウム利尿化合物複合体。
- 上記請求項のいずれかに記載のナトリウム利尿化合物複合体および薬学的に許容される担体を含む、医薬組成物。
- 請求項5ないし13に記載のナトリウム利尿化合物複合体を製造する方法であって、前記方法が前記修飾部分を前記ナトリウム利尿化合物に化学的に結合する工程を含む、方法。
- 上記請求項のいずれかに記載のナトリウム利尿化合物複合体の薬学的に純粋な組成物。
- mが1であり、Xが−O−であり、nが4であり、Cが−CH3である、請求項5に記載のナトリウム利尿化合物複合体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57443604P | 2004-05-26 | 2004-05-26 | |
PCT/US2005/019249 WO2005116655A2 (en) | 2004-05-26 | 2005-05-26 | Natriuretic compounds, conjugates, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008500375A JP2008500375A (ja) | 2008-01-10 |
JP2008500375A5 true JP2008500375A5 (ja) | 2008-05-22 |
Family
ID=35451511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007515532A Pending JP2008500375A (ja) | 2004-05-26 | 2005-05-26 | ナトリウム利尿化合物、複合体、およびその使用 |
Country Status (14)
Country | Link |
---|---|
US (3) | US7648962B2 (ja) |
EP (1) | EP1776132A4 (ja) |
JP (1) | JP2008500375A (ja) |
KR (1) | KR20070050876A (ja) |
CN (1) | CN101027073A (ja) |
AU (1) | AU2005248860A1 (ja) |
BR (1) | BRPI0511588A (ja) |
CA (1) | CA2568363A1 (ja) |
IL (1) | IL179521A0 (ja) |
MX (1) | MXPA06013810A (ja) |
NZ (1) | NZ552210A (ja) |
RU (1) | RU2388765C2 (ja) |
WO (1) | WO2005116655A2 (ja) |
ZA (1) | ZA200610700B (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
WO2006005140A2 (en) | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
US20080207505A1 (en) * | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
KR101529318B1 (ko) * | 2005-12-19 | 2015-06-16 | 파마인 코포레이션 | 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법 |
US20080064045A1 (en) | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
EP2150811B1 (en) * | 2007-05-08 | 2013-01-16 | Abbott Laboratories | Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms |
CA2693303C (en) * | 2007-07-20 | 2017-11-07 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
EP2612868B1 (en) * | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | C型ナトリウム利尿ペプチドの変異体 |
US20090286329A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratoires | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
US20090286256A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratories | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
US8449872B2 (en) * | 2008-09-19 | 2013-05-28 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
EP2898900B1 (en) * | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
US20110171161A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
CA2758581C (en) * | 2009-05-20 | 2022-06-14 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
CA2768810C (en) * | 2009-07-23 | 2014-05-20 | Igisu Co., Ltd. | Skin external-preparation composition |
JP5893561B2 (ja) * | 2009-09-25 | 2016-03-23 | シャイア・オーファン・セラピーズ・ゲーエムベーハーShire Orphan Therapies GmbH | 新規npr−bアゴニスト |
AR078446A1 (es) | 2009-12-18 | 2011-11-09 | Alcon Res Ltd | Agonistas de npr-b. uso. |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
CN102260345A (zh) * | 2011-05-17 | 2011-11-30 | 上海格尼生物技术有限公司 | 一种固相多肽合成人脑钠素的制备方法 |
WO2013032784A1 (en) | 2011-08-30 | 2013-03-07 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
WO2013070741A1 (en) * | 2011-11-11 | 2013-05-16 | Mayo Foundation For Medical Education And Research | Methods and materials for regulating natriuretic polypeptide function |
WO2013103896A1 (en) | 2012-01-06 | 2013-07-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2014209229A1 (en) * | 2013-06-25 | 2014-12-31 | National University Of Singapore | Vasodilation peptides and uses thereof |
EP3083701B1 (en) * | 2013-12-17 | 2019-08-07 | Novo Nordisk A/S | Enterokinase cleavable polypeptides |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
US10449236B2 (en) | 2014-12-05 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
JPWO2016194855A1 (ja) * | 2015-05-29 | 2018-06-07 | 株式会社 イギス | 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料 |
WO2017031114A1 (en) | 2015-08-17 | 2017-02-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
KR102518217B1 (ko) * | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
JP2019513711A (ja) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
EP3500289A4 (en) | 2016-08-18 | 2020-05-06 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING TRACHEOBRONCHOMALACIA |
EP3500592A4 (en) * | 2016-08-18 | 2020-08-12 | National University of Singapore | PEPTIDES WITH VASODILATOR AND / OR DIURETIC FUNCTIONS |
AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
RU2656188C1 (ru) * | 2017-05-03 | 2018-06-04 | Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") | Синтетическое анальгетическое средство пептидной природы и способ его применения |
AU2018328208A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Reversible linkers and use thereof |
AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
KR102546103B1 (ko) * | 2018-03-20 | 2023-06-21 | 니치유 가부시키가이샤 | 분기형 단분산 폴리에틸렌 글리콜, 중간체 및 그 제조 방법 |
EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
CN111848776B (zh) * | 2020-08-31 | 2022-03-18 | 江苏璟泽生物医药有限公司 | 聚乙二醇修饰的rhBNP及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2410789C2 (de) * | 1974-03-07 | 1980-08-07 | Hoechst Ag, 6000 Frankfurt | Verfahren zum Kaltmahlen von Cellulosederivaten |
US4130647A (en) * | 1977-07-08 | 1978-12-19 | Pfizer Inc. | Methods for treating congestive heart failure and ischemic heart disease |
EP0083367A1 (en) * | 1981-07-02 | 1983-07-13 | WALTON, Alan G. | Glycosaminoglycan drug complexes |
ATE37983T1 (de) * | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
US5037741A (en) * | 1986-08-18 | 1991-08-06 | The Coca Cola Company | Enzymatic method for the synthesis and separation of peptides |
JP2544929B2 (ja) | 1987-06-17 | 1996-10-16 | 第一化学薬品 株式会社 | 新規生理活性ペプチド |
US5114923A (en) * | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
CA1339210C (en) * | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US20020086843A1 (en) * | 1989-03-01 | 2002-07-04 | Daiichi Pure Chemicals Co., Ltd. | Physiologically active polypeptide and DNA |
US5342940A (en) | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
US5108568A (en) | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
JP2665850B2 (ja) * | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
GB9211686D0 (en) * | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5512459A (en) * | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
US5569794A (en) * | 1994-05-24 | 1996-10-29 | Alliedsignal Inc. | Vapor phase process for producing hydroflourocarbons from perchloroethylene having a phenolic inhibitor |
US6037145A (en) * | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
NO319913B1 (no) * | 1994-12-09 | 2005-10-03 | Shionogi & Co | Fremgangsmate til sandwichimmunoassay for N-peptid |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
ATE297950T1 (de) | 1996-03-04 | 2005-07-15 | Scios Inc | Testverfahren und reagenzien zur quantifizierung von hbnp |
US6028055A (en) * | 1996-10-22 | 2000-02-22 | Genetech, Inc. | Receptor selective BNP |
WO1998045329A1 (en) | 1997-04-04 | 1998-10-15 | Novo Nordisk A/S | Natriuretic peptide derivatives |
US6495514B1 (en) | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6117644A (en) * | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
ATE220917T1 (de) | 1999-01-26 | 2002-08-15 | Lilly Co Eli | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten |
AU765753B2 (en) | 1999-05-17 | 2003-09-25 | Conjuchem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
WO2004011498A2 (en) | 2002-07-31 | 2004-02-05 | Conjuchem Inc. | Long lasting natriuretic peptide derivatives |
WO2000071576A2 (en) * | 1999-05-24 | 2000-11-30 | Mayo Foundation For Medical Education And Research | Adenovirus vectors encoding brain natriuretic peptide |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
KR100345214B1 (ko) | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
DE60115465T2 (de) * | 2000-08-29 | 2006-08-03 | Nobex Corp. | Immunoregulierende verbindungen, deren derivate und ihre verwendung |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
ATE446971T1 (de) | 2001-09-07 | 2009-11-15 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
-
2004
- 2004-11-30 US US10/999,761 patent/US7648962B2/en not_active Expired - Fee Related
-
2005
- 2005-05-26 RU RU2006145827/04A patent/RU2388765C2/ru not_active IP Right Cessation
- 2005-05-26 AU AU2005248860A patent/AU2005248860A1/en not_active Abandoned
- 2005-05-26 KR KR1020067027333A patent/KR20070050876A/ko not_active Application Discontinuation
- 2005-05-26 US US11/138,194 patent/US20060074009A1/en not_active Abandoned
- 2005-05-26 CN CNA2005800252228A patent/CN101027073A/zh active Pending
- 2005-05-26 JP JP2007515532A patent/JP2008500375A/ja active Pending
- 2005-05-26 NZ NZ552210A patent/NZ552210A/en unknown
- 2005-05-26 BR BRPI0511588-4A patent/BRPI0511588A/pt not_active IP Right Cessation
- 2005-05-26 EP EP05780093A patent/EP1776132A4/en not_active Withdrawn
- 2005-05-26 WO PCT/US2005/019249 patent/WO2005116655A2/en active Application Filing
- 2005-05-26 CA CA002568363A patent/CA2568363A1/en not_active Abandoned
- 2005-05-26 MX MXPA06013810A patent/MXPA06013810A/es unknown
-
2006
- 2006-11-23 IL IL179521A patent/IL179521A0/en unknown
- 2006-12-19 ZA ZA200610700A patent/ZA200610700B/en unknown
-
2010
- 2010-01-19 US US12/689,342 patent/US20100216714A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008500375A5 (ja) | ||
RU2388765C2 (ru) | Натрийуретические соединения, конъюгаты и их применение | |
CN1081638C (zh) | 噻吩并嘧啶化合物 | |
ATE459370T1 (de) | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen | |
JP2004514663A5 (ja) | ||
JP2021100937A5 (ja) | ||
EP3518982A1 (en) | Incremental dose finding in controlled-release pth compounds | |
US20160206746A1 (en) | Method of preparing dendritic drugs | |
JP2005525302A5 (ja) | ||
NZ597499A (en) | Compounds and compositions for delivering active agents | |
JP2006526031A5 (ja) | ||
GEP20063860B (en) | Chemically-modified human growth hormone conjugates | |
JP2007510619A5 (ja) | ||
JP2004533444A5 (ja) | ||
JP2010517955A5 (ja) | ||
CY1114241T1 (el) | Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια | |
JP2013525414A5 (ja) | ||
EP2075250A3 (en) | Thrombin receptor antagonists | |
US20230381284A1 (en) | Controlled-Release PTH Compound | |
TWI770010B (zh) | 聚乙二醇衍生物及其用途 | |
JP2004517098A5 (ja) | ||
JP2001200034A5 (ja) | ||
JP2002520316A5 (ja) | ||
JP2009541288A5 (ja) | ||
RU2323211C2 (ru) | Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция |